Pune, India, May 14, 2019 (GLOBE NEWSWIRE) -- The study conducted by Market Research Future (MRFR) reveals that the global Epilepsy Market is anticipated to scale a valuation of USD 9,509.2 Mn towards the end of 2023. In addition, the report has further indicated that the market is expected to exhibit a CAGR of 8.20% during the forecast period 2018 to 2023.

Epilepsy is a chronic neurological disorder with a patient population of about 50 million. The increasing prevalence of the diseases is projected to boost the growth pattern of the epilepsy market in the years to come.

Although the disease is prevalent among children and adults alike, the older population is more at a risk of getting affected by the disorder. The rising geriatric population is prognosticated to have a positive influence on the expansion of the epilepsy market over the next couple of years. It is likely to motivate the industry leaders to invest in the development of more effective drugs and treatments. This, in turn, is expected to accelerate revenue creation for market players.

Request Free Sample @ https://www.marketresearchfuture.com/sample_request/7730

Brain injuries are proven to trigger post-traumatic epilepsy (PTE) and post-traumatic seizure (PTS) in many cases which is anticipated to drive the growth of the epilepsy market. Increasing cases of accidents and injuries are forecasted to encourage the growth pattern of the market in the upcoming years. Price erosion is expected to increase access to treatments as the majority of the patients belong to middle- and low-income countries. Thus, it is projected to propel market expansion over the next few years.

Key Players:

The noted players operating in the global epilepsy market are LivaNova PLC (U.K.), Johnson & Johnson Services Inc. (U.S.), Eisai Co. Ltd. (Japan), GlaxoSmithKline PLC (U.K.), Pfizer Inc. (U.S.), UCB SA (Belgium), Medtronic PLC (Ireland), NeuroPace Inc. (U.S.), Novartis AG (Switzerland), GW Pharmaceuticals PLC (U.K.), and Abbott Laboratories (U.S.).

Market Segmentation:

This MRFR report offers a detailed segmental analysis of the epilepsy market based on condition, diagnosis & treatment, and end-use. The market, by condition, has been bifurcated into epilepsy drug resistant / intractable epilepsy and others. The epilepsy drug resistant / intractable epilepsy held 29.5% market share in 2017 and is expected to strike a relatively higher CAGR over the assessment period. In addition, the others segment signifies growth potential and is anticipated to expand at 7.83% CAGR during the forecast period.

By diagnosis & treatment, the market has been divided into diagnosis and treatment. The diagnosis segment has been further sub-segmented into imaging devices, blood tests, and others. Again, the treatment segment has been sub-segmented into anti-epileptic drugs, neurostimulation devices, brain surgery, ketogenic diet, and others. The treatment segment accounted for the major share of the epilepsy market in 2017 and is likely to maintain its prominence owing to the availability of economically affordable options for treatment.

Based on end-use, the epilepsy market has been segmented into hospitals, clinics, ambulatory surgical centers, diagnostic centers, and others. Among these, the hospitals segment is projected to hold a significant share of the market over the next couple of years. It accounted for 29.3% share of the market in 2017.

Asia Pacific set to exceed USD 2000 Mn mark by 2023-end

The regional assessment of the global Epilepsy Market spans across Americas, Europe, Asia Pacific, and the Middle East and Africa (MEA). Americas held a 41% market share in 2017 and is projected to hold its position in the global marketplace through the forecast period. Europe, on the other hand, is an important growth pocket expected to reflect a CAGR of 8.31% over the review period. The region is anticipated to witness inflow of investments in research & development which is likely to favor the growth of the market. Additionally, the market is expected to flourish in Asia Pacific and reach a valuation of USD 2,046.57 Mn by 2023.

Browse the market data and information spread across 196 pages with 244 data tables and 23 figures of the report “Epilepsy Market- Forecast 2018-2023” in-depth alongside table of content (TOC) at: https://www.marketresearchfuture.com/reports/epilepsy-market-7730

Latest Industry News:

  • GW Pharmaceuticals, a British biopharmaceutical company, racked up sales of USD 33.5 Mn in its first full quarter for its cannabis-based seizure drug Epidiolex. The sales were worth more than double of what the analysts have predicted.
  • Expesicor, Montana-based company which is emphasizing on prevention and treatment of neurological disorders, has signed a collaboration agreement with San Diego-based biotechnology company, Novoron Bioscience, focused on treating disorders of the central nervous system. The collaboration is aimed at the development of neuro-regenerative compounds for epilepsy, Alzheimer’s disease, and ALS.

Browse Related Reports:

Epilepsy Diagnosis & Treatment Market Research Report, By Type (Idiopathic, Cryptogenic, Symptomatic), Diagnosis (Neurological Exam, Blood Test, Imaging), Treatment (Medication, Surgery) End-User (Hospitals, Clinics) - Global Forecast Till 2023
https://www.marketresearchfuture.com/reports/epilepsy-diagnosis-treatment-market-5647

Anti-epilepsy drugs Market Information, By Types of seizures (Generalized seizures and Partial-onset seizures), Generation (First, second and third) - Global Forecast to 2022
https://www.marketresearchfuture.com/reports/anti-epilepsy-drugs-market-2345

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +16468459312
Email: sales@marketresearchfuture.com